Market Overview

Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment

Related BMY
US Stock Futures Edge Lower Ahead Of Federal Budget
Morgan Stanley Downgrades Bristol-Myers On Valuation
Apple Leads the Charge as Earnings Season Heats Up (Fox Business)
Related MRK
Health Care And Biotech Sector Looking Sick
FTC Requests Public Comment on Merck & Co., Inc.'s Application to Approve Sale of Facilities
Making Money With Charles Payne: 12/8/14 (Fox Business)

Shares of Bristol-Myers Squibb (NYSE: BMY) fall 7.15% following Q4 results and management's announcement that the company will continue Phase 1 studies of nivolimab and Yervoy in lung cancer before advancing to Phase 3.

BMO Capital Markets analyst Alex Arfaei's noted that many investors expected a rapid advancement to stage 3 and this news will disappoint. Arfaei added that Bristol-Myer's management comments may be interpreted as a sign of caution.

The analyst reported that this news is “incrementally positive” for Merck & Co. (NYSE: MRK) who is developing a competing therapy in lung cancer, MK- 3475.

Arfaei rates Bristol-Myers as Market Perform with a $56.00 price target, and Merck as Outperform with a $56.00 price target.

Bristol-Myers is currently down 4.75% at $51.39 and shares of Merck are up 0.87% at $52.05.

Latest Ratings for BMY

DateFirmActionFromTo
Dec 2014JefferiesMaintainsHold
Nov 2014Morgan StanleyDowngradesOverweightEqual-weight
Nov 2014JP MorganMaintainsOverweight

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Alex Arfaei BMO Capital MarketsAnalyst Color News Analyst Ratings

 

Related Articles (BMY + MRK)

Around the Web, We're Loving...

Get Benzinga's Newsletters